Skip to content

Cancelled by the investigator A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)

A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030483
Enrollment
Unknown
Registered
2020-03-03
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel common type of coronavirus pneumonia

Interventions

treatment group :Ba duanjin

Sponsors

The first affiliated hospital of guangzhou university of Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) age: 18-75 years old (including threshold), regardless of gender; (2) compliance with the pneumonia diagnosis and treatment protocol for novel coronavirus infection - the diagnostic criteria for the trial version 6 (the latest version, which is currently updated to version 6). (3) the sixth version of the reference treatment scheme meets the common type standard; (4) no participation in traditional health exercise (ba duan jin, tai chi, wu qin xi or other fitness qigong) within 7 days; (5) steady gait and clear consciousness; (6) patients who agreed to participate in this study and voluntarily signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) asthma requiring daily treatment, any other chronic respiratory disease (2) patients with severe mental illness and severe neurosis.? (3) the risk stratification of exercise rehabilitation was assessed as high-risk patients or those who were restricted from activities for other reasons; (4) patients with severe renal insufficiency and liver insufficiency; (5) patients with severe copd, cor pulmonale or respiratory failure; (6) severe hematopoietic system, tumor and other serious primary diseases; (7) those who practice traditional Chinese medicine skills (ba duan jin, tai chi, wu qin xi or other fitness qigong) within 14 days. There are speech, cognitive impairment and other effects of communicators. (8) the sixth trial version of the reference diagnosis and treatment scheme is for patients with severe or critical criteria;

Countries

China

Contacts

Public ContactHe jing

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

sakeonel@126.com+86 13760661654

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026